Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 9/20 | 0.51 |
| ▸ | PYGL | P06737 | 3/20 | 0.51 |
| ▸ | PYGM | P11217 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2607191 | 0.90 | CYP51A1 (0.51) | CYP51A1PYGLPYGMRAB9AALDH1A1 | |
| SCHEMBL2107845 | 0.89 | CYP51A1 (0.53) | CYP51A1PYGLPYGMRAB9AALDH1A1 | |
| SCHEMBL2608563 | 0.88 | CYP51A1 (0.54) | CYP51A1PYGLPYGMUTS2R | |
| SCHEMBL2606797 | 0.87 | PYGL (0.53) | CYP51A1PYGLPYGM | |
| SCHEMBL2109016 | 0.87 | PYGL (0.53) | CYP51A1PYGLPYGM | |
| SCHEMBL2108267 | 0.85 | CYP51A1 (0.62) | CYP51A1PYGLPYGMRAB9A | |
| SCHEMBL2606950 | 0.85 | PYGL (0.52) | CYP51A1PYGLPYGMALDH1A1 | |
| SCHEMBL2606947 | 0.85 | PYGL (0.52) | CYP51A1PYGLPYGMALDH1A1 | |
| SCHEMBL2606894 | 0.84 | PYGL (0.51) | CYP51A1PYGLPYGMALDH1A1 | |
| SCHEMBL2606896 | 0.84 | PYGL (0.51) | CYP51A1PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | CYP51A1 598/4885PYGL 1/4885PYGM 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.